AstraZeneca: Liberum reiterates buy rating

(CercleFinance.com) - Liberum has confirmed its buy rating on the AstraZeneca share, maintaining its target price for it at 9220p.


The analyst believes that AstraZeneca's oncology division is central to its medium-term growth.

"We see oncology sales growing from $11bn in 2020 to $26bn by 2027. This business will drive superior sales growth, margin expansion and strong double-digit earnings growth," the broker says.

"Last night's data from Lynparza's OlympiA trial (in adjuvant breast cancer) further support its multi-billion dollar sales potential and reinforces our conviction in Astra's growth potential," Liberum adds.


Copyright (c) 2021 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.